Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP)’s share price fell 1.8% during mid-day trading on Tuesday . The stock traded as low as $9.40 and last traded at $9.53, with a volume of 62,259 shares changing hands. The stock had previously closed at $9.70.

Several brokerages have issued reports on AQXP. Canaccord Genuity reissued a “buy” rating and issued a $22.00 price target on shares of Aquinox Pharmaceuticals in a research note on Wednesday, August 17th. Zacks Investment Research lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 9th. Needham & Company LLC began coverage on Aquinox Pharmaceuticals in a research report on Thursday, May 12th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Jefferies Group upped their target price on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a “hold” rating in a research report on Friday, August 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $19.86.

The stock’s market cap is $155.60 million. The firm has a 50-day moving average price of $8.40 and a 200 day moving average price of $8.38.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by $0.22. On average, equities research analysts predict that Aquinox Pharmaceuticals Inc. will post ($2.08) EPS for the current fiscal year.

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company operates in the segment of identification and development of therapeutics in disease areas of inflammation and immuno-oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.